PMID- 19752007
OWN - NLM
STAT- MEDLINE
DCOM- 20100111
LR  - 20220408
IS  - 1460-2180 (Electronic)
IS  - 0143-3334 (Print)
IS  - 0143-3334 (Linking)
VI  - 31
IP  - 1
DP  - 2010 Jan
TI  - Epigenetics in cancer.
PG  - 27-36
LID - 10.1093/carcin/bgp220 [doi]
AB  - Epigenetic mechanisms are essential for normal development and maintenance of 
      tissue-specific gene expression patterns in mammals. Disruption of epigenetic 
      processes can lead to altered gene function and malignant cellular 
      transformation. Global changes in the epigenetic landscape are a hallmark of 
      cancer. The initiation and progression of cancer, traditionally seen as a genetic 
      disease, is now realized to involve epigenetic abnormalities along with genetic 
      alterations. Recent advancements in the rapidly evolving field of cancer 
      epigenetics have shown extensive reprogramming of every component of the 
      epigenetic machinery in cancer including DNA methylation, histone modifications, 
      nucleosome positioning and non-coding RNAs, specifically microRNA expression. The 
      reversible nature of epigenetic aberrations has led to the emergence of the 
      promising field of epigenetic therapy, which is already making progress with the 
      recent FDA approval of three epigenetic drugs for cancer treatment. In this 
      review, we discuss the current understanding of alterations in the epigenetic 
      landscape that occur in cancer compared with normal cells, the roles of these 
      changes in cancer initiation and progression, including the cancer stem cell 
      model, and the potential use of this knowledge in designing more effective 
      treatment strategies.
FAU - Sharma, Shikhar
AU  - Sharma S
AD  - Department of Urology, Biochemistry and Molecular Biology, USC/Norris 
      Comprehensive Cancer Center Keck School of Medicine, University of Southern 
      California, Los Angeles, CA 90089-9181, USA.
FAU - Kelly, Theresa K
AU  - Kelly TK
FAU - Jones, Peter A
AU  - Jones PA
LA  - eng
GR  - CA82422/CA/NCI NIH HHS/United States
GR  - CA83867/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
DEP - 20090913
PL  - England
TA  - Carcinogenesis
JT  - Carcinogenesis
JID - 8008055
RN  - 0 (MicroRNAs)
SB  - IM
MH  - *Epigenesis, Genetic
MH  - Humans
MH  - MicroRNAs/genetics
MH  - Neoplasms/*genetics/pathology
MH  - Neoplastic Stem Cells
PMC - PMC2802667
EDAT- 2009/09/16 06:00
MHDA- 2010/01/12 06:00
PMCR- 2011/01/01
CRDT- 2009/09/16 06:00
PHST- 2009/09/16 06:00 [entrez]
PHST- 2009/09/16 06:00 [pubmed]
PHST- 2010/01/12 06:00 [medline]
PHST- 2011/01/01 00:00 [pmc-release]
AID - bgp220 [pii]
AID - 10.1093/carcin/bgp220 [doi]
PST - ppublish
SO  - Carcinogenesis. 2010 Jan;31(1):27-36. doi: 10.1093/carcin/bgp220. Epub 2009 Sep 
      13.